Gadolinium contrast may be risky in kidney disease
AUTOR(ES)
Thomson, Peter C
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1906672Documentos Relacionados
- Hyperuricemia may be related to contrast-induced nephropathy after percutaneous coronary intervention
- Coronary artery disease in US may no longer be declining
- The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients
- Hemoglobin value may be decreased in patients with severe coronavirus disease 2019
- Amyloid β and Alzheimer disease therapeutics: the devil may be in the details